Challenges in U.S. Drug Approval and Pricing

This chapter explores the intricate landscape of drug approval and reimbursement systems in the U.S., focusing on Medicare's refusal to cover the costly Alzheimer's drug Aduhelm despite FDA approval. It contrasts American practices with those of other countries, emphasizing the need for cost-effectiveness analyses and regulatory reforms to enhance drug affordability. Additionally, the chapter navigates patient perspectives on medication costs, the need for reliable health information, and critiques the unregulated supplements market that can mislead patients.